This website uses cookies to understand how you use the website and to improve your experience. By continuing to use the website, you accept the University of New England’s use of cookies and similar technologies. To learn more about our use of cookies and how to manage your browser cookie settings, please review our Privacy Notice.


Study by UNE’s Edward Li published in leading specialty pharmacy journal

Ed Li

December 15, 2017

The Journal of Managed Care and Specialty Pharmacy has published research by Edward Li, M.P.H., BCOP, professor in the College of Pharmacy. Ernesto Lobaina (COP, ’19) served as a co-author of the study.

Their study is titled “Application of the FDA biosimilar extrapolation framework to make off-label determinations.” Through the FDA’s extrapolation framework, a biosimilar can obtain licensure for indications not explicitly studied in the context of a clinical trial. This structure enables conclusions from studies in one population to make inferences in other populations.

In their manuscript, Li and Lobaina describe the FDA extrapolation framework for evaluating whether there are any differences in the mechanism of action, pharmacokinetics/biosdistribution, immunogenicity and toxicity between on-label and off-label indications. They conclude that in some cases, the use of biosimilars for off-label indications can be scientifically justified. 

Read the study.


To learn more about the University of New England’s College of Pharmacy, visit

To apply, visit

Groups audience: